US HB3105 | 2019-2020 | 116th Congress
Status
Spectrum: Partisan Bill (Democrat 1-0)
Status: Introduced on June 5 2019 - 25% progression, died in committee
Action: 2019-06-06 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on June 5 2019 - 25% progression, died in committee
Action: 2019-06-06 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Summary
Requires the Department of Health and Human Services to assess market-share-based fees, for the next 10 years, on drug manufacturers that have produced opioid drugs since 1999. Opioid drugs manufactured to treat opioid addiction, cancer patients, or hospice patients are, however, exempt from this assessment. All assessed fees must be used for the substance abuse prevention and treatment block grant program.
Title
Opioid Treatment Surge Act
Sponsors
| Rep. Suzanne Bonamici [D-OR] |
History
| Date | Chamber | Action |
|---|---|---|
| 2019-06-06 | House | Referred to the Subcommittee on Health. |
| 2019-06-05 | House | Referred to the House Committee on Energy and Commerce. |
| 2019-06-05 | House | Introduced in House |
Same As/Similar To
SB1662 (Same As) 2019-05-23 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Subjects
Drug, alcohol, tobacco use
Health
Health care coverage and access
Prescription drugs
User charges and fees
Health
Health care coverage and access
Prescription drugs
User charges and fees
US Congress State Sources
| Type | Source |
|---|---|
| Summary | https://www.congress.gov/bill/116th-congress/house-bill/3105/all-info |
| Text | https://www.congress.gov/116/bills/hr3105/BILLS-116hr3105ih.pdf |
